Seroprevalence of Neutralizing Antibodies in Healthy Adults, in Mexico, Against Human and Simian Adenovirus Types
Authors:
- Raúl E. LópezRLRaúl E. López
- Margarita Valdés AlemánMAMargarita Valdés Alemán
- Jesús M. Torres-FloresJTJesús M. Torres-Flores
- Yordanis Pérez-LlanoYPYordanis Pérez-Llano
- David Alejandro Cabrera GaytánDGDavid Alejandro Cabrera Gaytán
- Clara Esperanza Santacruz TinocoCTClara Esperanza Santacruz Tinoco
- Julio Elias Alvarado YaahJYJulio Elias Alvarado Yaah
- Yu Mei Anguiano HernándezYHYu Mei Anguiano Hernández
- Bernardo Martínez MiguelBMBernardo Martínez Miguel
- José Esteban Muñoz MedinaJMJosé Esteban Muñoz Medina
- Nancy Sandoval GutiérrezNGNancy Sandoval Gutiérrez
- Ilse Ramos LagunesILIlse Ramos Lagunes
Open Access
Abstract
Replication-defective adenoviruses are widely used as vectors for vaccines, but their efficacy may be compromised by the prevalence of pre-existing neutralizing antibodies from natural infections or prior vaccination with adenovirus-based vaccines. To overcome these limitations, less common human adenovirus (HAdV) types and simian adenoviruses (SAdV) have been explored as alternative vectors to the widely prevalent HAdV-C5. Despite their importance, there is limited information on the epidemiology of adenovirus immunity in many countries and geographical regions, including Mexico. In this study, we analyzed 2488 serum samples from healthy adults across all 32 states of Mexico to assess the prevalence of both total and neutralizing antibodies against various HAdV types from species A-F, and three related SAdVs. Our findings indicate a high prevalence of neutralizing antibodies against HAdV-C5 and HAdV-C6, with significant cross-reactivity observed among related adenoviruses. Notably, HAdV-D26 exhibited a lower prevalence of neutralizing antibodies, suggesting its potential suitability as a vector for vaccine development in populations with high pre-existing immunity to more common HAdV types. These results provide critical insights for optimizing adenovirus-based vaccine strategies in Mexico.Keywords
Funding Information
- Conahcyt (F003: C-52-2021, F003: 321211, PRONAII: 303081, PRONAII: 302965)
This publication has 60 references indexed in Scilit:
- Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10Molecular Therapy-Oncolytics, 2022
- Seroprevalence and molecular characterization of human respiratory syncytial virus and human adenovirus among children in Ado‐Ekiti, NigeriaJournal of Medical Virology, 2021
- Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, ChinaVirologica Sinica, 2020
- In silico identification of potential epitopes present in human adenovirus proteins for vaccine design and of putative drugs for treatment against viral infectionJournal of Immunological Methods, 2018
- Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola VaccinesJAMA, 2016
- International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populationsVaccine, 2011
- International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trialsVaccine, 2010
- Molecular modeling and epitopes mapping of human adenovirus type 3 hexon proteinVaccine, 2009
- Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IXMolecular Therapy, 2000
- Adenovirus infection in cystic fibrosis patients: Implications for the use of adenoviral vectors for gene transferInfection, 1996